Table 2 HR and 95% CIs for the risk of outcomes (n = 59,423), follow for 3 years
Outcome | Cohort | ||
|---|---|---|---|
Patients with outcome | Survival probability at end of time window | HR (95% CI) | |
1. Cardiovascular diseases | |||
HPV vaccine | 1935 | 95.678% | 0.9 (0.847, 0.957) |
Non-HPV vaccine | 2168 | 95.26% | Reference |
2. Cerebrovascular diseases | |||
HPV vaccine | 125 | 99.706% | 0.605 (0.484, 0.754) |
Non-HPV vaccine | 210 | 99.528% | Reference |
3. Heart dysfunction | |||
HPV vaccine | 266 | 99.386% | 0.833 (0.708, 0.98) |
Non-HPV vaccine | 324 | 99.274% | Reference |
4. Composite outcome | |||
HPV vaccine | 2024 | 95.471% | 0.878 (0.827, 0.932) |
Non-HPV vaccine | 2324 | 94.915% | Reference |